Xevudy Helps GSK Ride Out Depressed Shingrix Sales
But COVID-19 Profits Will Drop In 2022
Executive Summary
GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.
You may also be interested in...
Coronavirus Update: Canadian Evusheld Supply Deal, Nuvaxovid EU Shipments
The US places certain limits on the use of GSK's Xevudy, while Canada signs a supply deal for another antibody therapy, AstraZeneca's Evusheld. Meanwhile, Novavax starts EU shipments of its vaccine and the UK funds ConserV's pan-coronavirus vaccine.
Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.